Pregled bibliografske jedinice broj: 1000804
HIV-1 transmitted drug resistance in Slovenia and its impact on predicted treatment effectiveness: 2011-2016 update
HIV-1 transmitted drug resistance in Slovenia and its impact on predicted treatment effectiveness: 2011-2016 update // PLoS One, 13 (2018), 4; e0196670-e0196670 doi:10.1371/journal.pone.0196670 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1000804 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
HIV-1 transmitted drug resistance in Slovenia and its impact on predicted treatment effectiveness: 2011-2016 update
Autori
Lunar, Maja ; Židovec Lepej, Snježana ; Tomazic, Janez ; Vovko, Tomaz D ; Pecavar, Blaž ; Turel, Gabriele ; Maver, Manja ; Poljak, Mario
Izvornik
PLoS One (1932-6203) 13
(2018), 4;
E0196670-e0196670
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
non-B subtypes ; naive patients ; prevalence ; europe ; epidemiology ; transmission ; performance ; population ; sequences ; Greece
Sažetak
HIV-positive individuals that have a detected transmitted drug resistance (TDR) at baseline have a higher risk of virological failure with antiretroviral therapy (ART). This study offers an update on the prevalence of TDR in Slovenia, looks for onward transmission of TDR, and reassesses the need for baseline drug resistance testing. Blinded questionnaires and partial pol sequences were obtained from 54.5% (168/308) of all of the patients diagnosed with HIV-1 from 2011 to 2016. Subtype B was detected in 82.7% (139/168) of patients, followed by subtype A (8.3%), subtype C (2.4%), and CRF01_AE (1.8%). Surveillance drug resistance mutations (SDRMs) were found in four individuals (2.4%), all of them men who have sex with men (MSM) and infected with subtype B. K103N was detected in two patients and T68D and T215D in one person each, corresponding to a prevalence of 0%, 1.2%, and 1.2% of TDR to protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), and non-NRTIs (NNRTIs), respectively. The impact of mutations on drug susceptibility was found to be most pronounced for NNRTIs. No forward spread of TDR within the country was observed ; however, phylogenetic analysis revealed several new introductions of HIV into Slovenia in recent years, possibly due to increased risky behavior by MSM. This was indirectly confirmed by a substantial increase in syphilis cases and HIV-1 non-B sub-types during the study period. A drug-resistant HIV variant with good transmission fitness is thus more likely to be imported into Slovenia in the near future, and so TDR should be closely monitored.
Izvorni jezik
Engleski
POVEZANOST RADA
Projekti:
143-1080116-0097 - Imunološka rekonstitucija i rezistencija na lijekove u HIV-bolesnika iz Hrvatske (Židovec-Lepej, Snježana, MZOS ) ( CroRIS)
Ustanove:
Klinika za infektivne bolesti "Dr Fran Mihaljević"
Profili:
Snježana Židovec-Lepej
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE